Breast cancer impacts over 2 million women around the world each year.
Following radiotherapy or chemotherapy, breast-conserving surgery is the first line of intervention for early-stage breast cancer.
This surgery aims to remove the tumour while preserving as much of the healthy tissue as possible, but since precise tumour mapping during surgery is challenging, sometimes the tumour is not fully extracted.
Without proper removal, patients face future surgeries, delayed follow-up treatments, and a decreased quality of life.
In APL Bioengineering, by AIP Publishing, researchers from the University of Western Australia, the University of Melbourne, the Royal Melbourne Hospital, and Nicolaus Copernicus University in Toruń designed and tested a hand-held device to differentiate tumours from healthy tissue using the tissues’ mechanical properties.
Often, tumours are stiffer than benign tissue — a difference that can be felt during surgery.
“The technique presented in this paper — stereoscopic optical palpation (SOP) — was inspired by clinical palpation, which is routinely used by surgeons to identify diseased tissue based on the sense of touch,” author Rhys Jones said.
The hand-held probe the researchers developed is based on optical elastography, a field that combines imaging with mechanical measurements like elasticity.
When compressed, tumours and healthy tissue exhibit different mechanical properties, and this can be measured by the probe.
Since the probe also provides a visual of the tissue, users have another data point to differentiate the two tissue types.
“The wireless probe is an extension of previous benchtop implementations of SOP,” Jones said.
“Our process began with establishing key requirements for the probe through consultation with surgeons: We decided that our targets were an ergonomic hand-held format, a field of view of at least 6 millimetres by 6 millimetres, wireless operation, a minimum one-hour battery life, and low material costs.”
The material cost of the prototype was around $1,200, which is less than similar benchtop SOP devices priced around $3,000, but the authors believe this can be reduced if it is mass-produced.
Ultimately, Jones wants the device to be used in vivo during surgery, even going beyond tumour removal.
“Beyond breast-conserving surgery, we believe that the probe could be used in many clinical scenarios where palpation is currently used, including the assessment of skin lesions,” Jones said.
Source: American Institute of Physics
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.